Furthermore, support for a potential metformin treatment mediated by reducing serum levels of insulin and other metabolic markers, such as serum levels of glucose, leptin, and high-sensitivity C-reactive protein (hsCRP) in a group of breast cancer patients was provided [164]. This evidence concerns the gene INS and breast carcinoma.